PUBLIC RESEARCH DOSSIER
COAG · NasdaqHemab Therapeutics Holdings, Inc.
Manufacturing · Biological Products, (No Diagnostic Substances)完成交易日收盘US$43.1+4.66%行情日期 2026-11-03 · 非实时
公开资料页汇总Hemab Therapeutics Holdings, Inc.(COAG)的已发布行情、估值、风险、财务摘要与同业对比。行情截至2026-11-03,非实时;缺失值不按零处理。
股价走势
复权收盘价(美元)
2026-05-01 — 2026-11-03129 个交易日样本历史覆盖不足所选区间,已显示实际可用范围。
COAGUS$43.1
查看图表数据
| 日期 | COAG |
|---|---|
| 2026-05-01 | 34 |
| 2026-05-04 | 25.34 |
| 2026-05-05 | 25 |
| 2026-05-06 | 25.01 |
| 2026-05-07 | 25.74 |
| 2026-05-08 | 25.12 |
| 2026-05-11 | 25 |
| 2026-05-12 | 25.9 |
| 2026-05-13 | 28.56 |
| 2026-05-14 | 28.37 |
| 2026-05-15 | 28.07 |
| 2026-05-18 | 27.15 |
| 2026-05-19 | 25.44 |
| 2026-05-20 | 26.47 |
| 2026-05-21 | 26.3 |
| 2026-05-22 | 25.89 |
| 2026-05-26 | 27.84 |
| 2026-05-27 | 28.6 |
| 2026-05-28 | 28 |
| 2026-05-29 | 28.5 |
| 2026-06-01 | 27.13 |
| 2026-06-02 | 27.47 |
| 2026-06-03 | 26.17 |
| 2026-06-04 | 25.41 |
| 2026-06-05 | 25.3 |
| 2026-06-08 | 25.55 |
| 2026-06-09 | 27 |
| 2026-06-10 | 25.55 |
| 2026-06-11 | 26.94 |
| 2026-06-12 | 24.98 |
| 2026-06-15 | 25.08 |
| 2026-06-16 | 25.51 |
| 2026-06-17 | 26.45 |
| 2026-06-18 | 29.24 |
| 2026-06-22 | 31.74 |
| 2026-06-23 | 29.15 |
| 2026-06-24 | 28.76 |
| 2026-06-25 | 27.72 |
| 2026-06-26 | 32.37 |
| 2026-06-29 | 36.73 |
| 2026-06-30 | 36.73 |
| 2026-07-01 | 32.5 |
| 2026-07-02 | 31 |
| 2026-07-06 | 29.97 |
| 2026-07-07 | 31.49 |
| 2026-07-08 | 33.89 |
| 2026-07-09 | 37.2 |
| 2026-07-10 | 38.03 |
| 2026-07-13 | 39.51 |
| 2026-07-14 | 43.31 |
| 2026-07-15 | 43.32 |
| 2026-07-16 | 44.53 |
| 2026-07-17 | 49.29 |
| 2026-07-20 | 49.39 |
| 2026-07-21 | 48.28 |
| 2026-07-22 | 49.23 |
| 2026-07-23 | 45.83 |
| 2026-07-24 | 47.31 |
| 2026-07-27 | 50.39 |
| 2026-07-28 | 47.26 |
| 2026-07-29 | 44.75 |
| 2026-07-30 | 47.47 |
| 2026-07-31 | 47.55 |
| 2026-08-03 | 45 |
| 2026-08-04 | 46.52 |
| 2026-08-05 | 50.09 |
| 2026-08-06 | 52.16 |
| 2026-08-07 | 49.66 |
| 2026-08-10 | 49.87 |
| 2026-08-11 | 51.74 |
| 2026-08-12 | 53.48 |
| 2026-08-13 | 53.95 |
| 2026-08-14 | 54.94 |
| 2026-08-17 | 53.59 |
| 2026-08-18 | 52.44 |
| 2026-08-19 | 51.66 |
| 2026-08-20 | 48.2 |
| 2026-08-21 | 49.16 |
| 2026-08-24 | 46.67 |
| 2026-08-25 | 49.65 |
| 2026-08-26 | 49.19 |
| 2026-08-27 | 49.49 |
| 2026-08-28 | 44.84 |
| 2026-08-31 | 45.73 |
| 2026-09-01 | 44.02 |
| 2026-09-02 | 44.7 |
| 2026-09-03 | 44.37 |
| 2026-09-04 | 44.41 |
| 2026-09-08 | 44.57 |
| 2026-09-09 | 44.5 |
| 2026-09-10 | 39.88 |
| 2026-09-11 | 39.4 |
| 2026-09-14 | 40.47 |
| 2026-09-15 | 40.11 |
| 2026-09-16 | 40.97 |
| 2026-09-17 | 41.22 |
| 2026-09-18 | 41.19 |
| 2026-09-21 | 37.97 |
| 2026-09-22 | 38.25 |
| 2026-09-23 | 36.73 |
| 2026-09-24 | 35.72 |
| 2026-09-25 | 34.74 |
| 2026-09-28 | 33.12 |
| 2026-09-29 | 32.6 |
| 2026-09-30 | 30.84 |
| 2026-10-01 | 31.06 |
| 2026-10-02 | 31.11 |
| 2026-10-05 | 30.59 |
| 2026-10-06 | 28.37 |
| 2026-10-07 | 28.7 |
| 2026-10-08 | 30.89 |
| 2026-10-09 | 31.62 |
| 2026-10-12 | 30.39 |
| 2026-10-13 | 29.8 |
| 2026-10-14 | 29.94 |
| 2026-10-15 | 32.52 |
| 2026-10-16 | 30.07 |
| 2026-10-19 | 32.09 |
| 2026-10-20 | 34.17 |
| 2026-10-21 | 35.34 |
| 2026-10-22 | 34.82 |
| 2026-10-23 | 34.4 |
| 2026-10-26 | 36.02 |
| 2026-10-27 | 38.4 |
| 2026-10-28 | 38.5 |
| 2026-10-29 | 40.42 |
| 2026-10-30 | 41.45 |
| 2026-11-02 | 41.18 |
| 2026-11-03 | 43.1 |
1、3、6、12个月分别按21、63、126、252个交易日取区间;缺失日期不从区间外补齐。
使用已有每日复权收盘样本,非实时行情;图中价格可能与未复权收盘报价不同。
01 · MARKET FRAME
行情、估值与风险
基于已完成交易日和已发布财务资料
区间涨跌幅
区间涨跌幅使用复权收盘价;估值和风险指标缺失时显示为—,不按零处理。
02 · FINANCIAL TRACE
财务摘要
公开页仅显示最近3个已校验报告期
年度财务走势
百万美元 · 年度报告期
所选指标暂无已校验的年度资料,缺失值不按零处理。
| 指标 | 2026-07-31 | 2026-06-30 |
|---|---|---|
| 营收 | — | — |
| 净利润 | — | — |
| 自由现金流 | — | — |
| 股份数 | 46.7 | — |
| 债务 | — | — |
| 总资产 | — | 467.8 |
金额及股份数均以百万为单位。缺失或待核验数据不按零处理。
03 · PEER SET
同业对比
同一细分行业中市值最接近的公司
| 公司 | 市值 | 近250日涨跌幅 | 市盈率 | 距52周高点 | 波动率 |
|---|---|---|---|---|---|
| REPL瑞普利缪恩 | US$2B | +130.2% | — | +6% | +187.1% |
| VCELVericel Corp | US$2.1B | +13.4% | 86.9× | -14.9% | +41.2% |
| VIR维尔生物技术 | US$1.9B | +113.7% | — | -6% | +64.1% |
| BCRX百奥克里斯特制药 | US$2.2B | +26.8% | — | -22.9% | +48.1% |
同业由已覆盖公司的行业分类和市值接近度确定,仅用于横向研究;缺失数据不按零处理。
